Cross Border Grants
Cross Border Grants facilitate international collaboration between researchers in the field of Alzheimer’s and dementia research.
- Researchers can apply for up to €200,000 for a period of two years.
- Funding is awarded to projects that significantly advance our understanding of Alzheimer’s disease or related dementias in the fields of basic research, diagnostics, prevention and therapy.
- Applications must be submitted jointly by a researcher from Germany and a researcher from another country. The partner researcher will be funded by Alzheimer Nederland (Netherlands), Fondation Vaincre Alzheimer (France), or the BrightFocus Foundation (worldwide – see guidelines).
- For more details, please refer to the guidelines on this page.
Applications must be submitted via the AIMS application platform.
Questions about the application process or funding conditions? Please see our FAQ for Scientists.
Dr. Anne Pfitzer-Bilsing
Director of Scientific Affairs
Tel.: 0211 - 86 20 66 14
E-Mail
Schedule - Cross Border Grants
- Call for Application: closed
- Deadline Letter of Intent: closed
- Review by European Scientific Advisory Board: undergoing
- Notification to applicants regarding the request for a full application: May 2026
- Deadline full application: June 23, 1 pm
- Review by European Scientific Advisory Board and external reviewers: June - October 2026
- Notifying applicants of grant awards and denials: November 2026
- Start of the project: January 1, 2027
Downloads
AFI uses an online application system. Applications (letters of intent) for Cross Border grants can be submitted there in English from January 2, 2026 (closed).
AFI Application Instructions Cross-Border Grant 2026
1. AIMS User Manual - Registration, Accessibility, and Cookies
2. AIMS User Manual - Navigating AIMS after Logging In
3. AIMS User Manual - Filling out the Letter of Intent Form
4. AIMS User Manual - Filling out the Full Proposal Form
Templates for annual reports will be sent to you via mail by the scientific administration individually.




